Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2020-03-30 Audit Report / Informat…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
사업보고서 (2019.12)
Audit Report / Information Classification · 98% confidence The document is a formal 'Audit Report' (감사보고서) for ABL Bio, covering the fiscal year 2019. It includes the independent auditor's report from Samjong KPMG, the financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. It is not an Annual Report (10-K) as it lacks the comprehensive management discussion and analysis (MD&A) and business overview typical of a full 10-K, and it is not an Earnings Release (ER) as it is a full audited financial package. Therefore, it is classified as an Audit Report. FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, dividend decisions, and the appointment of directors and audit committee members. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which captures the official outcomes of shareholder votes at a general meeting.
2020-03-24 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and vesting conditions. In the context of financial filings, the issuance of stock options or changes in capital structure related to employee compensation plans is classified under 'Share Issue/Capital Change' (SHA) as it represents a potential change in the company's equity structure.
2020-03-24 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This type of disclosure specifically concerns changes in the composition of the board of directors. According to the provided definitions, announcements regarding changes in the board of directors fall under the 'Board/Management Information' (MANG) category.
2020-03-24 Korean
투자판단관련주요경영사항(ABL001 국내 제1b/2a상 임상시험 계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding the approval of a Phase 1b/2a clinical trial by the Ministry of Food and Drug Safety (MFDS). It is a specific disclosure of a material business event ('투자판단 관련 주요경영사항') related to clinical trial progress. Since it does not fit into specific categories like M&A, dividends, or financial reports, and serves as a formal regulatory disclosure of a material event, it is classified as a Regulatory Filing (RNS).
2020-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (unqualified/proper), key financial data, and details regarding the auditor (Samjong Accounting Corp). While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report (10-K) or a standalone audit report document (AR). Following the 'Menu vs Meal' rule, this is a regulatory filing announcement. FY 2019
2020-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.